References
- Penali LK, Jansen FH. Single-day, three-dose treatment with fixed-dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria. Int. J. Infect. Dis.12(4), 430–437 (2008).
- Ramharter M, Kurth F, Schreier AC et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis.198(6), 911–919 (2008).
- Zongo I, Dorsey G, Rouamba N et al. Artemether–lumefantrine versus amodiaquine plus sulfadoxine–pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet369(9560), 491–498 (2007).
- Adjei GO, Kurtzhals JA, Rodrigues OP et al. Amodiaquine–artesunate vs artemether–lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar. J.7, 127 (2008).
- Ashley EA, Stepniewska K, Lindegardh N et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health12(2), 195–200 (2007).
- Abdulla S, Sagara I, Borrmann S et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet DOI:10.1016/S0140-6736(08)61492-0 (2008) (Epub ahead of print).
Websites
- Medicines for Malaria Venture. Development projects. PYRAMAX® (pyronaridine artesunate) – Phase III www.mmv.org/article.php3?id_article=48 (Accessed 8 September 2008)
- Medicines for Malaria Vanture. Development projects. Eurartesim® (dihydroartemisinin piperaquine) – Phase III www.mmv.org/article.php3?id_article=52 (Accessed 8 September 2008)